Here's the more detailed FDA approval letter: https://www.fda.gov/media/151710/download

Regarding your comment. I know several people who have already quit, many looking for new jobs and many who have shored up their finances. Many who have had the vaccine have explicitly stated they would never get their kids vaccinated. So there's also that...

I also know probably 10 families who have up and moved to Texas and Florida in 2021.

Here's follow up studies in specified in the letter:

4. Study C4591009, entitled “A Non-Interventional Post-Approval Safety Study of the Pfizer-BioNTech COVID-19 mRNA Vaccine in the United States,” to evaluate the occurrence of myocarditis and pericarditis following administration of COMIRNATY. We acknowledge the timetable you submitted on August 21, 2021, which states that you will conduct this study according to the following schedule:

- Final Protocol Submission: August 31, 2021

- Monitoring Report Submission: October 31, 2022

- Interim Report Submission: October 31, 2023

- Study Completion: June 30, 2025

- Final Report Submission: October 31, 2025

5. Study C4591021, entitled “Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine,” to evaluate the occurrence of myocarditis and pericarditis following administration of COMIRNATY. We acknowledge the timetable you submitted on August 21, 2021, which states that you will conduct this study according to the following schedule:

- Final Protocol Submission: August 11, 2021

- Progress Report Submission: September 30, 2021

- Interim Report 1 Submission: March 31, 2022

- Interim Report 2 Submission: September 30, 2022

- Interim Report 3 Submission: March 31, 2023

- Interim Report 4 Submission: September 30, 2023

- Interim Report 5 Submission: March 31, 2024

- Study Completion: March 31, 2024

- Final Report Submission: September 30, 2024

6. Study C4591021 substudy to describe the natural history of myocarditis and pericarditis following administration of COMIRNATY. We acknowledge the timetable you submitted on August 21, 2021, which states that you will conduct this study according to the following schedule:

- Final Protocol Submission: January 31, 2022

- Study Completion: March 31, 2024

- Final Report Submission: September 30, 2024

7. Study C4591036, a prospective cohort study with at least 5 years of follow-up for potential long-term sequelae of myocarditis after vaccination (in collaboration with Pediatric Heart Network). We acknowledge the timetable you submitted on August 21, 2021, which states that you will conduct this study according to the following schedule:

- Final Protocol Submission: November 30, 2021

- Study Completion: December 31, 2026

- Final Report Submission: May 31, 2027

8. Study C4591007 substudy to prospectively assess the incidence of subclinical myocarditis following administration of the second dose of COMIRNATY in a subset of participants 5 through 15 years of age. We acknowledge the timetable you submitted on August 21, 2021, which states that you will conduct this assessment according to the following schedule:

- Final Protocol Submission: September 30, 2021

- Study Completion: November 30, 2023

- Final Report Submission: May 31, 2024

9. Study C4591031 substudy to prospectively assess the incidence of subclinical myocarditis following administration of a third dose of COMIRNATY in a subset of participants 16 to 30 years of age. We acknowledge the timetable you submitted on August 21, 2021, which states that you will conduct this study according to the following schedule:

- Final Protocol Submission: November 30, 2021

- Study Completion: June 30, 2022

- Final Report Submission: December 31, 2022

10. Study C4591022, entitled “Pfizer-BioNTech COVID-19 Vaccine Exposure during Pregnancy: A Non-Interventional Post-Approval Safety Study of Pregnancy and Infant Outcomes in the Organization of Teratology Information Specialists (OTIS)/MotherToBaby Pregnancy Registry.”

- Final Protocol Submission: July 1, 2021

- Study Completion: June 30, 2025

- Final Report Submission: December 31, 2025

11. Study C4591007 substudy to evaluate the immunogenicity and safety of lower dose levels of COMIRNATY in individuals 12 through <30 years of age.

- Final Protocol Submission: September 30, 2021

- Study Completion: November 30, 2023

- Final Report Submission: May 31, 2024

12. Study C4591012, entitled “Post-emergency Use Authorization Active Safety Surveillance Study Among Individuals in the Veteran’s Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine.”

- Final Protocol Submission: January 29, 2021

- Study Completion: June 30, 2023

- Final Report Submission: December 31, 2023

13. Study C4591014, entitled “Pfizer-BioNTech COVID-19 BNT162b2 Vaccine Effectiveness Study - Kaiser Permanente Southern California.”

- Final Protocol Submission: March 22, 2021

- Study Completion: December 31, 2022

- Final Report Submission: June 30, 2023